Drug Profile
Research programme: diabetes and obesity therapeutics - NGM Biopharmaceuticals/AstraZeneca
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune; NGM Biopharmaceuticals
- Developer NGM Biopharmaceuticals
- Class Antibodies; Peptide hormones
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Obesity in USA
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
- 17 Jun 2013 Early research in Obesity in USA (unspecified route)